Skip to main content

MRI Measure May ID Men at Risk for Postradiation Genitourinary Toxicity

Medically reviewed by Carmen Pope, BPharm. Last updated on Dec 1, 2023.

By Lori Solomon HealthDay Reporter

FRIDAY, Dec. 1, 2023 -- Longer prostatic urethral length measured on prostate magnetic resonance imaging (MRI) is independently associated with a higher risk for developing late genitourinary (GU) toxicity after radiation therapy (RT) for prostate cancer, according to a study published online Oct. 17 in Academic Radiology.

Joseph Lee, M.D., Ph.D., from the Corewell Health William Beaumont University Hospital in Royal Oak, Michigan, and colleagues evaluated pretreatment prostate quantitative MRI measurements and clinical characteristics in predicting GU toxicity after RT for prostate cancer. The analysis included 361 men (June 2016 to February 2023).

The researchers found that 14.4 percent of men experienced grade ≥2 acute toxicity. Brachytherapy (odds ratio, 2.9) was associated with higher odds of acute GU toxicity, while longer membranous urethral length (odds ratio, 0.41) was associated with decreased odds. Median follow-up for late toxicity was 15.0 months with approximately 88.7 percent of patients free of toxicity at one year and 72.0 percent free at three years. An increased risk for late GU toxicity was associated with longer prostatic urethral length (hazard ratio, 1.6), particularly urinary frequency/urgency symptoms (hazard ratio, 1.7).

"This pretreatment metric may be potentially valuable in risk-stratification models for quality of life following prostate RT," the authors write.

Abstract/Full Text (subscription or payment may be required)

Disclaimer: Statistical data in medical articles provide general trends and do not pertain to individuals. Individual factors can vary greatly. Always seek personalized medical advice for individual healthcare decisions.

© 2024 HealthDay. All rights reserved.

Posted December 2023

Read this next

Tumor-Infiltrating Lymphocyte Abundance Prognostic in Early-Stage TNBC

THURSDAY, April 18, 2024 -- For patients with early-stage triple-negative breast cancer (TNBC) who undergo surgery without chemotherapy, tumor-infiltrating lymphocyte (TIL)...

Transient Increase Seen in Contraceptive Use After Dobbs Decision

MONDAY, April 15, 2024 -- A transient increase in contraceptive use was seen following the Dobbs v Jackson Women's Health Organization decision, with a return to overall downward...

Microwave Ablation Feasible for T1N0M0 Papillary Thyroid Carcinoma

FRIDAY, April 12, 2024 -- For patients with multifocal papillary thyroid carcinoma (PTC), the rates of progression-free survival (PFS) do not differ between microwave ablation...

More news resources

Subscribe to our newsletter

Whatever your topic of interest, subscribe to our newsletters to get the best of Drugs.com in your inbox.